

## **Risk Stratification of Advanced Fibrosis in HIV Patients With Hepatic Steatosis Using the NAFLD Fibrosis and BARD Scores**

George A. YENDEWA <sup>1,2\*</sup>, Ana KHAZAN <sup>1</sup>, Jeffrey M. JACOBSON <sup>1,2</sup>

<sup>1</sup> Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

<sup>2</sup> Division of Infectious Diseases and HIV Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA

**Key words:** *HIV, liver, steatosis, obesity, NAFLD, NASH, metabolic disorders, diagnostics*

**\* Corresponding author:**

**George A. Yendewa, MD, MPH&TM**

Assistant Professor of Medicine (Infectious Diseases)  
Case Reserve Western University School of Medicine  
Division of Infectious Diseases and HIV Medicine  
University Hospitals Cleveland Medical Center  
11100 Euclid Ave, Cleveland, OH 44106, USA  
Telephone: +1 216-844-1988  
Fax: +1 216-844-1632  
E-mail: [gay7@case.edu](mailto:gay7@case.edu)

## ABSTRACT

**Background:** Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent in people with HIV (PWH), yet the risk factors for disease progression are poorly understood, due to inadequate surveillance. We employed non-invasive methods to estimate the prevalence and associated factors of advanced NAFLD in PWH.

**Methods:** We conducted a retrospective study of PWH enrolled in our clinic from 2005 to 2022. We employed imaging (ultrasound, computer tomography, magnetic resonance imaging, and transient elastography) or biopsy reports to identify cases of hepatic steatosis. We excluded patients with harmful alcohol use, hepatitis B or C infection, and other specified etiologies. We used the NAFLD Fibrosis Score (NFS), BARD Score, AST to Platelet Index (APRI), and Fibrosis-4 (FIB-4) Score to stratify fibrosis. We used logistic regression to identify predictors of advanced fibrosis.

**Results:** Among 3959 PWH in care, 1201 had available imaging or liver biopsies. After exclusions, 114 of the remaining 783 had evidence of hepatic steatosis (prevalence 14.6%). The majority were male (71.1%), with mean age 46.1 years, and mean body mass index (BMI)  $31.4 \pm 8.1$  kg/m<sup>2</sup>. About 24% had lean NAFLD (BMI < 25 kg/m<sup>2</sup>). Based on the NFS, 27.2% had advanced fibrosis, which was corroborated by estimates from the other scores. In adjusted regression analysis, advanced fibrosis was associated with BMI > 35 kg/m<sup>2</sup> (4.43, 1.27-15.48), thrombocytopenia (4.85, 1.27-18.62) and hypoalbuminemia (9.01, 2.39-33.91).

**Conclusion:** We found a NAFLD prevalence of 14.6%, with 27.2% of cases having advanced fibrosis. Our study provides practical insights into the surveillance of NAFLD in PWH.

## INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) is a growing global health problem. NAFLD results from the accumulation of fat in hepatocytes (steatosis) in the absence of a specified etiology such as alcohol use disorder, hepatitis B (HBV) or C (HCV), autoimmune hepatitis, Wilson's disease, and other hereditary metabolic disorders [1]. Clinically, two main phenotypes are recognized: non-alcoholic fatty liver (NAFL), which is characterized by the accumulation of fat in hepatocytes with minimal inflammation/damage, and non-alcoholic steatohepatitis (NASH), in which significant hepatocellular damage and/or fibrosis has occurred [1]. According to recent estimates, NAFLD affects about 37.8% of the general population worldwide, a dramatic rise from a prevalence of 25.5% before 2005 [2]. The growing problem of NAFLD/NASH closely parallels rising trends in the global burden of classic risk factors such as obesity, type 2 diabetes mellitus, and the metabolic syndrome [1]. The presence of the NASH phenotype is associated with a higher risk of progression to cirrhosis and hepatocellular carcinoma (HCC) [3]. Consequently, NAFLD/NASH has now surpassed HCV as the leading indication for liver transplantation in developed countries [4].

NAFLD is a frequent, yet underappreciated cause of chronic liver disease among people living with HIV (PWH), however, prevalence estimates may vary widely depending on the diagnostic method used. A systematic review and meta-analysis of 10 studies published in 2017 estimated a NAFLD prevalence of 35% among HIV mono-infected individuals [5], which is comparable to NAFLD rates reported in the general population [2]. However, in addition to established risk factors for NAFLD [1], PWH are susceptible to multiple pathophysiologic mechanisms of hepatocellular injury which may further increase their risk of NAFLD. Specifically, HIV-associated inflammation and immune activation accompanying HIV replication in Kupfer and hepatic stellate cells induces mitochondrial toxicity and promotes a profibrogenic microenvironment within the liver parenchyma [6-8]. Additional HIV-specific mechanisms that have been implicated in the development of NAFLD include HIV-induced enteropathy and alterations in the gut microbiome [7, 9, 10] and toxicities associated with antiretroviral treatment (ART) regimens such as older generation nucleos(t)ide reverse transcriptase inhibitors (NTRIs), protease inhibitors (PIs), and the newer generation integrase strand inhibitors (INSTI) [11-13].

As the life expectancy of PWH has dramatically increased in the era of combination ART, it is anticipated that PWH will remain at increased risk of NAFLD and other noncommunicable diseases associated with aging [14, 15]. Unfortunately, current management strategies for NAFLD such as lifestyle modifications and pharmacologic therapy have limited efficacy in advanced disease, which often requires more extreme interventions including bariatric surgery or liver transplantation [14, 15]. It is therefore essential that NAFLD is identified early for appropriate counseling, risk stratification, and management. However, diagnosing NAFLD can be challenging even in well-resourced settings. Liver biopsy, which is the gold standard for diagnosis and staging, is invasive and carries inherent risks. Noninvasive imaging methods such as transient elastography have been validated in PWH and provide highly accurate and reliable measurements of liver fibrosis [16-18]; however, they are costly and not always available in routine clinical practice. As a result, several predictive non-invasive scoring systems have been developed such as the NAFLD Fibrosis Score (NFS) [19] and the BARD Score [20]. These scores utilize routine laboratory tests and anthropometric measures and have demonstrated acceptable diagnostic performance, which has led to their increasing use as alternative diagnostic tools for detecting NAFLD in both the general population and PWH [19-22].

In this study, we aimed to estimate the prevalence of NAFLD and identify risk factors associated with advanced disease (i.e., NASH) in a university hospital-based HIV cohort in Northeast Ohio in the United States using non-invasive scores for detecting liver fibrosis.

## METHODS

### Study Design, Setting and Cohort

We conducted a retrospective cross-sectional study by reviewing the medical records of HIV-infected patients who received routine care at the Special Immunology Unit (SIU) at the University Hospitals Cleveland Medical Center in Cleveland, Ohio, United States from 2005 to 2022. The SIU was established in 1985 to provide comprehensive clinical care to PWH or those at risk of acquiring HIV infection, including HIV testing, counseling and support services, ART, pre-exposure prophylaxis, and clinical trials. To date, the SIU has provided clinical care to over 4000 PWH, with 1214 patients actively in care in 2022.

### Data Extraction and Study Definitions

The study inclusion criteria were age  $\geq 18$  years with at least one visit to the SIU between 2005 and 2022, documented evidence of HIV infection (i.e., antibody/antigen testing, polymerase chain reaction, or Western blot), and evidence of hepatic steatosis based on characteristic findings on ultrasonography, computed tomography, magnetic resonance imaging, or transient elastography, or liver biopsy report. Exclusion criteria were documented significant alcohol use disorder, HBV or HCV infection, autoimmune hepatitis, Wilson's disease, hemochromatosis, primary biliary sclerosis, drug-induced liver injury, and other liver diseases of specified etiology such as cholestatic, metabolic, or genetic liver-related diseases.

We extracted demographic, clinical, and laboratory data from the medical records of patients who met the study inclusion criteria. We collected data on age, sex, race/ethnicity, body mass index (BMI), alcohol use, smoking history, drug history, comorbidities (i.e., hypertension, prediabetes, diabetes, obesity, and dyslipidemia), angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs), statins, anti-diabetic agents (i.e., insulin and metformin), ART history and HIV indices (i.e., CD4 count and viral load). Additional laboratory data collected included platelet count, hemoglobin A1c (HbA1c), serum aspartate transaminase (AST), alanine transaminase (ALT), bilirubin (total and direct), albumin, and lipid panel (total cholesterol, high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C), and triglycerides(TG)). All laboratory data extracted were within 6 months of the diagnosis of hepatic steatosis.

We calculated the BMI using the formula  $\text{mass}(\text{kg})/\text{height}^2(\text{m}^2)$  and classified participants as underweight (i.e., BMI  $< 18.5 \text{ kg/m}^2$ ), normal (i.e., BMI  $18.5\text{-}24.9 \text{ kg/m}^2$ ), overweight (i.e., BMI  $25\text{-}29.9 \text{ kg/m}^2$ ), obese (i.e., BMI  $30\text{-}34.9 \text{ kg/m}^2$ ), and morbidly obese (i.e., BMI  $\geq 35 \text{ kg/m}^2$ ) [23]. We defined prediabetes as an HbA1c of 5.7% to 6.4%, and diabetes as an HbA1c  $\geq 6.5\%$  or being on anti-diabetic treatment [24]. We defined hypertension as documented blood pressure  $\geq 140/90$  mmHg or being on antihypertensive treatment [25]. We used the harmonized criteria for the metabolic syndrome to define dyslipidemia thresholds as follows: hypertriglyceridemia (TG  $\geq 150$  mg/dL), low HDL-C (i.e., HDL-C  $< 40$  mg/dL for males or  $< 50$  mg/dL for females), high LDL-C (i.e., LDL-C  $> 100$  mg/dL), and hypercholesterolemia (i.e., total cholesterol  $\geq 200$  mg/dL) [26].

### Non-invasive Assessments of Liver Fibrosis

We used four validated non-invasive scoring systems to estimate the degree of liver fibrosis. The Aspartate Transaminase to Platelet Ratio (APRI) Score was calculated using the formula:

$$\text{APRI} = [\text{AST (IU/L)}/\text{AST (Upper Limit of Normal) (IU/L)}]/[\text{Platelet Count (109/L)}] \times 100 \text{ [27].}$$

The following thresholds defined the degree of fibrosis: APRI  $< 0.5$  for normal liver histology, APRI  $0.5\text{-}1.5$  for significant fibrosis, and APRI  $> 1.5$  for advanced fibrosis [27].

We calculated the FIB-4 Score using the formula:

$$\text{FIB-4} = [\text{Age (years)} \times \text{AST (IU/L)}] / [\text{Platelet Count (10}^9\text{/L)} \times [\text{ALT (IU/L)}]^{1/2}] \text{ [28].}$$

A FIB-4 score < 1.45 was classified as normal liver, a FIB-4 Score of 1.45 to 3.25 as significant fibrosis, and a FIB-4 Score > 3.25 as advanced fibrosis [28].

We calculated the BARD Score using the BMI, AST/ALT ratio, and the presence or absence of type 2 diabetes mellitus to predict advanced fibrosis in NAFLD as originally described by Harrison *et al* [20]. The maximum possible BARD Score is 4, with BMI > 28 kg/m<sup>2</sup> scored as 1, AS/ALT > 0.8 scored as 2 and DM scored as 1. A BARD Score of 0-1 indicates a low probability of fibrosis and can rule out the need for a liver biopsy, while a score of 2-4 indicates an odds for advanced fibrosis of 17 (95% CI 9.2 to 31.9), with a negative predictive value of 96% [20].

Lastly, we calculated the NFS using the formula:

$$\text{NFS} = -1.675 + 0.037 \times \text{Age (year)} + 0.094 \times \text{BMI (kg/m}^2\text{)} + 1.13 \times \text{IFG/Diabetes (Yes = 1, No = 0)} + 0.99 \times \text{AST/ALT} - 0.013 \times \text{Platelet Count (}\times 10^9\text{/L)} - 0.66 \times \text{Albumin (g/dL)} \text{ [19],}$$

where IFG represents the presence of impaired fasting glucose. The degree of fibrosis was categorized as follows: NFS < -1.5 for normal liver, NFS  $\geq$  -1.5 to < 0.67 for mild/moderate fibrosis, and NFS  $\geq$  0.67 for a high probability of advanced fibrosis or NASH [19].

## Statistical Analyses

We performed statistical analyses using SPSS Version 29.0 (Armonk, NY; IBM Corp). We reported categorical variables as frequencies (percentages) and assessed associations using Pearson's chi-square or Fisher's exact tests. We presented continuous variables as means (standard deviations, SD) and assessed associations using the independent Student *t*-test. We used logistic regression models to identify associations between advanced and mild/moderate NAFLD. We evaluated known risk factors and potential disease modifiers of NAFLD in univariate analysis. Only covariates which attained a p-value of < 0.20 in the univariate analysis were included in the multivariate regression model. We reported associations as crude (OR) and adjusted odds ratios (AOR) with 95% confidence intervals (CI). In all analyses, p < 0.05 was considered statistically significant.

## Ethical Approval

We obtained ethical approval from the University Hospitals Cleveland Medical Center Institutional Review Board. Informed consent was not deemed necessary since the study involved only de-identified information.

## RESULTS

### Prevalence of NAFLD

Among 3959 PWH who received care at our clinic between 2005 and 2022, 1201 had available imaging or liver biopsy reports. A further 418 PWH with known etiologies for liver disease were excluded. Of the remaining 783, 114 had imaging or biopsy evidence of hepatic steatosis, yielding a NAFLD prevalence of 14.6% (Figure 1).

### General characteristics and classification of NAFLD

Table 1 describes the characteristics of the study population. Of the 114 PWH with NAFLD, 81 (71.1%) were male. The mean age was  $46.1 \pm 11.0$  years and the majority (59, 51.8%) were Black. The mean BMI was  $31.4 \pm 8.1$  kg/m<sup>2</sup>, with 24 (21.1%) categorized as normal/underweight (BMI < 25 kg/m<sup>2</sup>), while 35 (30.7%) were morbidly obese (BMI > 35 kg/m<sup>2</sup>). The majority were current or past smokers (73, 64.0%) and about one-third (36, 31.6%) had a history of drug use. The majority had hypertension (65, 57.0%), over one-third (42, 36.8%) were diabetic, and 25 (21.9%) had hyperlipidemia. The mean CD4 count was  $574 \pm 418$  cells/mm<sup>3</sup> and 107 (93.9%) were virologically suppressed. All were on ART, with 96 (84.2%) on a tenofovir-based regimen, 55 (48.2%) on INSTIs, 33 (28.9%) on PIs, and 26 (22.8%) on NNRTIs.

Based on the NFS estimates, 36 (31.6%) had normal liver architecture (NFS < -1.5), 47 (41.2%) had mild-to-moderate fibrosis ( $-1.5 \leq \text{NFS} < 0.67$ ), and 31 (27.2%) had advanced fibrosis/NASH (NFS  $\geq 0.67$ ). These results were in agreement with estimates from the APRI, FIB-4, and BARD scores (Table 1). According to the BARD scores, 25 patients (21.9%) had a low probability of fibrosis and could avoid having a liver biopsy.

### Comparison of patient characteristics of mild/moderate and advanced fibrosis

Compared with those with mild/moderate fibrosis, PWH with advanced fibrosis/NASH were significantly more likely to have higher BMI (mean  $35.6 \pm 9.8$  kg/m<sup>2</sup> vs  $29.8 \pm 6.9$  kg/m<sup>2</sup>,  $p < 0.001$ ), lower platelet counts (mean  $171 \pm 80 \times 10^9/\text{L}$  vs  $241 \pm 95 \times 10^9/\text{L}$ ,  $p < 0.001$ ), elevated AST (mean  $198 \pm 280$  IU/L vs  $71 \pm 79$  IU/L,  $p < 0.001$ ), higher direct bilirubin levels (mean  $1.0 \pm 1.7$  mg/mL vs  $0.5 \pm 0.9$  mg/mL,  $p = 0.027$ ), and lower albumin levels (mean  $3.1 \pm 0.9$  mg/dL vs  $4.0 \pm 0.7$  mg/dL,  $p < 0.001$ ) (Table 2). There was no difference between the groups in terms of sociodemographic factors, comorbidities, CD4 count, HIV viremia, class of ART, serum lipid profile, or potential modifiers of liver fibrosis such as antihypertensives, antidiabetics, and statins.

### Predictors of advanced fibrosis

In adjusted multiple logistic regression analysis, advanced fibrosis was significantly associated with BMI > 35 kg/m<sup>2</sup> (AOR 4.43, 95% CI [1.27-15.48];  $p = 0.020$ ), thrombocytopenia (AOR 4.85, 95% CI [1.27-18.62];  $p = 0.021$ ) and hypoalbuminemia (AOR 9.01, 95% CI [2.39-33.91];  $p < 0.001$ ) (Table 3).

## DISCUSSION

In this study, we estimated NAFLD prevalence of 14.6% in our HIV cohort, of which 27.2% had advanced fibrosis or NASH using non-invasive scores. Comparatively, HIV cohort studies from North America and Europe have reported higher NAFLD prevalence rates ranging from 25% to 75% [30-34]. Several factors could account for the underdiagnosis of NAFLD among PWH. Firstly, many studies, like others, primarily rely on liver ultrasonography, readily available but less sensitive diagnostic method compared with liver biopsy and transient elastography. Secondly, classic NAFLD symptoms may be absent, subclinical, or overlap with more frequently encountered conditions such as ART-related toxicities, metabolic disorders, and co-infections with HBV or HCV. Additionally, healthcare providers may have limited awareness about NAFLD in the context of HIV; this can result in delayed identification, risk stratification, and management of NAFLD.

Our study had a few findings worthy of further discussion. Firstly, despite the well-known association between high BMI and NAFLD, a significant proportion (up to 24%) of our patients with NAFLD had normal BMI or were underweight, a condition referred to as lean NAFLD [35]. Studies have reported that between 7% and 20% of people diagnosed with NAFLD fall into this category [36-38], highlighting the complex relationship between body weight and liver health. The underlying pathophysiologic mechanisms of lean NAFLD has not been elucidated; however, the emerging evidence points to distinct mechanisms contributing to NAFLD in the absence of central visceral adiposity [35]. These include impaired glucose metabolism, dysfunctional adipose tissue, and genetic factors such as carriage of the *PNPLA3* minor allele [39]. Furthermore, recent genome-wide investigations have revealed a potential association between NAFLD susceptibility and specific *HLA* alleles, such as *HLA-B\*54:01*, suggesting a potential influence of gut microbiota alterations [40]. These findings highlight the need for further research to better understand the pathophysiologic mechanisms of lean NAFLD. Moreover, clinicians should be vigilant in considering the possibility of NAFLD in non-obese patients presenting with liver-related symptoms, unexplained derangements in liver function tests, or other relevant risk factors.

Secondly, all non-invasive scores used were in agreement in stratifying liver fibrosis. Approximately 25-30% of our cohort had advanced fibrosis, while about 22% had a low probability of fibrosis, effectively ruling out the necessity for a liver biopsy. The BARD Score in particular merits further consideration as it offers some advantages over the NFS, APRI, and FIB-4. The BARD Score utilizes easily obtainable clinical parameters (i.e., BMI, AST/ALT ratio, and the presence of diabetes), making it convenient for routine clinical practice [20]. In comparison, the NFS, APRI, and FIB-4 scores require more complex calculations or additional laboratory values. Furthermore, the BARD Score, like the NFS, incorporates the presence of diabetes, a key component of the metabolic syndrome and a major predictor of CVD and NAFLD risk [26]. This additional parameter enhances the predictive ability of the BARD Score in identifying advanced liver fibrosis. Moreover, extensive studies and validations [41, 42] have shown that the BARD Score, as demonstrated by Harrison et al [30] in the original study, reliably eliminates the need for liver biopsy. Taken together, the noninvasive scores offer accurate risk stratification, reduce invasive procedures, and provide cost-effective monitoring for NAFLD patients.

Thirdly, we identified surrogate markers of advanced fibrosis that could have practical implications in the routine clinical management of patients. Individuals with a BMI > 35 kg/m<sup>2</sup> had a 4.4-fold higher odds of advanced fibrosis, while thrombocytopenia and hypoalbuminemia conferred a 4.85-fold and 9-fold increased odds of advanced liver disease, respectively. Thrombocytopenia has been widely used as a marker of advanced liver disease due to other etiologies such as cirrhosis and HCC [43, 44], as well as for progressive NAFLD specifically [45, 46]. Similarly, some studies have reported associations between hypoalbuminemia and advanced NAFLD, especially in chronic kidney disease [47-49]. Furthermore, chronological changes in these indices may also have prognostic significance. For instance, a study by Kawaguchi *et al* [49] showed that a decline in serum albumin of 0.21 g/dL/year was significantly associated with a

higher incidence of serious events in advanced NAFLD patients such as HCC, gastroesophageal varices, and cardiovascular events [49]. Thus, these readily obtainable indices can provide a practical means of alerting clinicians to NAFLD progression and aid in risk stratification.

Additionally, we did not observe any significant effect of statins, antihypertensives, or anti-diabetic treatment on the development of advanced fibrosis. This finding aligns with the current conflicting evidence regarding the impact of pharmacological agents on NAFLD. For example, a 2013 Cochrane review by Eslami *et al* [50] reported improvements in mortality, histological features, and biochemical profiles of NAFLD patients with statin use. However, the review included only two clinical trials with a small number of participants and a high risk of bias [51, 52]. Similarly, some studies have reported improvements in the biochemical profile, histological features, and liver-related events in NAFLD/NASH patients treated with ACE-Is/ARBs [53], insulin [54], and metformin [55], but not NASH resolution. However, recent studies have provided evidence supporting the favorable impact of semaglutide, a potent glucagon-like peptide-1 receptor agonist commonly used for the treatment of diabetes and obesity, on improving liver histology, liver function, lipid profile, or NAFLD/NASH resolution, mostly in diabetic patients [56-57], while other studies have produced contrary findings [58, 59]. Further studies are required, especially in the HIV population, to evaluate the efficacy of these pharmacological interventions in the management of NAFLD and NASH.

Lastly, we did not observe significant association between the class of ART and the degree of fibrosis, likely due to the small sample size of our study. Although ART has significantly prolonged the lifespan of PWH, it is associated with various side effects, including HIV-associated lipodystrophy and NAFLD [11-13, 35, 60]. The risk of developing NAFLD is influenced by several factors including the specific type and duration of the ART regimen, with older generation NRTIs and ritonavir-boosted PIs in particular and newer INSTIs being associated with a higher risk [60]. Oxidative stress resulting from ART-associated mitochondrial toxicity and insulin resistance appears to be the primary mechanisms contributing to the development of NAFLD [61, 62]. Despite this, the occurrence of ART-related NAFLD is relatively rare [60].

We acknowledge limitations that are inherent to our study design. These include limited generalizability due to the small sample size and restriction to a single health center. With a larger sample size, we could have potentially identified significant associations that were not apparent in our study. Furthermore, our reliance on non-invasive scores and ultrasound liver imaging may have introduced limitations and potential biases compared to more accurate diagnostic methods like liver biopsy or transient elastography. Despite these limitations, the study provides practical insights into diagnosing and managing NAFLD in PWH, which is often challenging even in well-resourced settings.



## CONCLUSION

In summary, we estimated an overall NAFLD prevalence of 14.6% in an Ohio-based HIV cohort using liver imaging criteria. Of these, we estimated an advanced fibrosis prevalence of 25% to 30% using non-invasive scores, while about 22% were stratified as low-risk for liver fibrosis, effectively reducing the need for liver biopsy. Factors associated with advanced fibrosis included BMI > 35 kg/m<sup>2</sup>, thrombocytopenia, and hypoalbuminemia. Our findings provide practical insights into the diagnosis and management of NALFD among PWH in routine clinical practice.

## **AUTHOR CONTRIBUTIONS**

GAY and JMJ conceptualized and designed the study. GAY collected the data and conducted the statistical analysis. AK contributed important intellectual content. GAY and AK drafted the initial manuscript version. All authors critically revised and approved of the final version. GAY is acting as the guarantor of this manuscript.

## **ACKNOWLEDGEMENTS**

We wish to acknowledge Kimberly Robbins, Database Manager for the Case AIDS Clinical Trials Unit for her helping with data extraction and management.

## **FUNDING INFORMATION**

This research was funded by grants from the National Institutes of Health (NIH)/AIDS Clinical Trials Group (ACTG) under Award Numbers AI068636 (1560GYD212) (G.A.Y.) and 5UM1AI069501-17 (J.M.J.)

## **CONFLICTS OF INTEREST**

The authors report no relevant financial disclosures or conflicts of interests.


## **DATA AVAILABILITY STATEMENT**

The data presented in this study are available on request from the corresponding author upon reasonable request.

## **ETHICAL APPROVAL**

We obtained ethical approval from the University Hospitals Cleveland Medical Center Institutional Review Board. Informed consent was not deemed necessary since the study involved only de-identified information.

**Figure 1.** Flow chart demonstrating inclusion and exclusion of study participants



CT, computer tomography; HIV, human immunodeficiency virus; MRI, magnetic resonance imaging; NAFLD, nonalcoholic fatty liver disease; PWH, people with HIV; SIU, Special Immunology Unit; TE, transient elastography.

\*Cases are not necessarily mutually exclusive to other conditions.

**Table 1.** Baseline demographic and clinical characteristics of PWH with NAFLD

| Characteristics                      | N (%)           |
|--------------------------------------|-----------------|
| Male sex                             | 81 (71.1)       |
| Age (years)                          |                 |
| Mean $\pm$ SD                        | 46.1 $\pm$ 11.0 |
| $\leq$ 34                            | 19 (16.7)       |
| 35-44                                | 25 (21.9)       |
| 45-54                                | 44 (38.6)       |
| $\geq$ 55                            | 26 (22.8)       |
| Race/ethnicity                       |                 |
| Black                                | 59 (51.8)       |
| White                                | 51 (44.7)       |
| Hispanic                             | 3 (2.6)         |
| Asian                                | 1 (0.9)         |
| Body mass index (kg/m <sup>2</sup> ) |                 |
| Mean $\pm$ SD                        | 31.4 $\pm$ 8.1  |
| <18.5 (underweight)                  | 3 (2.6)         |
| 18.5-24.9 (normal)                   | 21 (18.4)       |
| 25.0-29.9 (preobesity)               | 32 (28.1)       |
| 30.0-34.9 (obesity)                  | 23 (20.2)       |
| $\geq$ 35.0 (morbid obesity)         | 35 (30.7)       |
| Life-style associated risk factors   |                 |
| Smoking                              | 73 (64.0)       |
| Drug use                             | 36 (31.6)       |
| Comorbidities                        |                 |
| Hypertension                         | 65 (57.0)       |
| Hyperlipidemia                       | 25 (21.9)       |
| Diabetes                             | 42 (36.8)       |
| CD4 count (cells/mm <sup>3</sup> )   |                 |
| Mean $\pm$ SD                        | 574 $\pm$ 418   |
| $\geq$ 200                           | 94 (82.5)       |
| HIV RNA < 20 copies/mL               | 107 (93.9)      |
| ART regimen                          |                 |
| Tenofovir-based                      | 96 (84.2)       |
| INSTI-based                          | 55 (48.2)       |
| PI-based                             | 33 (28.9)       |
| NNRTI-based                          | 26 (22.8)       |
| Antihypertensives                    |                 |
| ACE-I or ARB                         | 41 (36.0)       |
| Others                               | 24 (21.1)       |
| Lipid-lowering agent                 |                 |
| Statin                               | 47 (41.2)       |
| Others                               | 6 (5.3)         |
| Antidiabetic treatment               |                 |
| Insulin plus other(s)                | 16 (14.0)       |
| Insulin alone                        | 8 (7.0)         |
| Metformin                            | 12 (10.5)       |

|                       |                  |
|-----------------------|------------------|
| APRI Score            |                  |
| Mean $\pm$ SD         | 1.75 $\pm$ 4.01  |
| > 1.5 (F3-F4)         | 36 (29.3)        |
| FIB-4 Score           |                  |
| Mean $\pm$ SD         | 3.75 $\pm$ 6.96  |
| > 3.25 (F3-F4)        | 28 (24.6)        |
| BARD Score            |                  |
| Mean $\pm$ SD         | 2.32 $\pm$ 1.08  |
| 0-1                   | 25 (21.9)        |
| 2-4                   | 89 (78.1)        |
| NAFLD Score           |                  |
| Mean $\pm$ SD         | -0.09 $\pm$ 3.02 |
| < -1.45 (F0)          | 36 (31.6)        |
| -1.45 to 0.67 (F1-F2) | 47 (41.2)        |
| $\geq$ 0.67 (F3-F4)   | 31 (27.2)        |

ACE-I, angiotensin-converting enzyme inhibitor; APRI, aspartate aminotransferase (AST) to platelet ratio index; ARB, angiotensin receptor blocker; ART, antiretroviral therapy; BARD score, body mass index, AST/alanine transaminase (ALT) ratio and diabetes score; FIB-4, fibrosis index based on 4 factors; HDL-C, high density lipoprotein; INSTI, integrase strand transfer inhibitor; LDL-C, low density lipoprotein; NAFLD, nonalcoholic fatty liver disease; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitors.

**Table 2.** Comparison of mild/moderate and advanced fibrosis by selected parameters

| Characteristics                              | Advanced fibrosis | Mild/moderate            | p-Value          |
|--|-------------------|--------------------------|------------------|
|  | F3-F4<br>(n=31)   | fibrosis F0-F2<br>(n=83) |                  |
| Age (years) <sup>a</sup>                     | 46.4 ± 11.4       | 46.0 ± 10.9              | 0.884            |
| Male sex, n (%)                              | 18 (58.1)         | 63 (75.9)                | 0.062            |
| Race/ethnicity, n (%)                        |                   |                          |                  |
| Black  | 17 (54.8)         | 42 (50.6)                | 0.841            |
| White  | 14 (45.2)         | 37 (44.6)                |                  |
| Hispanic                                     | -                 | 3 (3.6)                  |                  |
| Asian  | -                 | 1 (1.2)                  |                  |
| Body mass index (kg/m <sup>2</sup> )         | 35.6 ± 9.8        | 29.8 ± 6.9               | <b>&lt;0.001</b> |
| Smoking, n (%)                               | 17 (54.8)         | 56 (67.5)                | 0.211            |
| Drug use, n (%)                              | 6 (19.4)          | 30 (36.1)                | 0.086            |
| Hypertension, n (%)                          | 14 (45.2)         | 51 (61.4)                | 0.118            |
| Prediabetes or diabetes, n (%)               | 14 (45.2)         | 39 (47.0)                | 0.862            |
| CD4 count (cells/mm <sup>3</sup> )           | 470 ± 335         | 613 ± 440                | 0.106            |
| HIV RNA < 20 copies/mL, n (%)                | 1 (3.2)           | 6 (7.2)                  | 0.428            |
| ART regimen, n (%)                           |                   |                          |                  |
| Tenofovir-based                              | 27 (87.1)         | 69 (83.1)                | 0.606            |
| NNRI-based                                   | 8 (25.8)          | 18 (21.7)                | 0.855            |
| PI-based                                     | 8 (25.8)          | 25 (30.1)                |                  |
| INSTI-based                                  | 15 (48.4)         | 40 (48.2)                |                  |
| ACE-I or ARB use                             | 12 (38.7)         | 29 (34.9)                | 0.709            |
| Statin use, n (%)                            | 9 (29.0)          | 38 (45.8)                | 0.106            |
| Insulin, n (%)                               | 2 (6.5)           | 6 (7.2)                  | 0.885            |
| Metformin, n (%)                             | 3 (9.7)           | 17 (20.5)                | 0.177            |
| Platelets (x10 <sup>9</sup> /L) <sup>a</sup> | 171 ± 80          | 241 ± 95                 | <b>&lt;0.001</b> |
| AST (IU/L) <sup>a</sup>                      | 198 ± 280         | 71 ± 79                  | <b>&lt;0.001</b> |
| ALT (IU/L) <sup>a</sup>                      | 59 ± 55           | 76 ± 73                  | 0.234            |
| Total bilirubin (mg/dL) <sup>a</sup>         | 1.8 ± 2.7         | 1.2 ± 1.6                | 0.170            |
| Direct bilirubin (mg/dL) <sup>a</sup>        | 1.0 ± 1.7         | 0.5 ± 0.9                | <b>0.027</b>     |
| Albumin (g/dL) <sup>a</sup>                  | 3.1 ± 0.9         | 4.0 ± 0.7                | <b>&lt;0.001</b> |
| Total cholesterol (mg/dL) <sup>a</sup>       | 177 ± 56          | 188 ± 47                 | 0.302            |
| HDL-C (mg/dL) <sup>a</sup>                   | 44 ± 23           | 43 ± 18                  | 0.929            |
| LDL-C (mg/dL) <sup>a</sup>                   | 102 ± 65          | 102 ± 45                 | 0.992            |
| Triglycerides (mg/dL)                        | 265 ± 190         | 235 ± 167                | 0.410            |
| APRI <sup>a</sup>                            | 4.6 ± 8.3         | 1.1 ± 1.5                | <b>&lt;0.001</b> |
| FIB-4 <sup>a</sup>                           | 8.8 ± 11.6        | 1.9 ± 2.0                | <b>&lt;0.001</b> |
| BARD score <sup>a</sup>                      | 3.0 ± 0.7         | 2.1 ± 1.1                | <b>&lt;0.001</b> |

ACE-I, angiotensin-converting enzyme inhibitor; APRI, aspartate aminotransferase (AST) to platelet ratio index; ARB, angiotensin receptor blocker; ART, antiretroviral therapy; BARD score, body mass index, AST/alanine transaminase (ALT) ratio and diabetes score; FIB-4, fibrosis index based on 4 factors; HIV, human immunodeficiency virus; INSTI, integrase strand transfer inhibitor; HDL-C, high density lipoprotein; LDL-C, low density lipoprotein; NAFLD, nonalcoholic fatty liver disease; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitors; RNA, ribonucleic acid.

<sup>a</sup> mean ± standard deviation

**Table 3.** Factors Associated With Advanced NAFLD in PWH

| Characteristics                     | Univariate                |                  | Multivariate                 |              |
|-------------------------------------|---------------------------|------------------|------------------------------|--------------|
|                                     | Crude Odds Ratio (95% CI) | p-Value          | Adjusted Odds Ratio (95% CI) | p-Value      |
| Age > 45 years                      | 0.89 (0.39-2.03)          | 0.774            |                              |              |
| Male sex                            | 0.44 (0.18-1.05)          | 0.062            | 0.60 (0.18-2.00)             | 0.407        |
| Black race/ethnicity                | 1.19 (0.52-2.71)          | 0.687            |                              |              |
| BMI ≥ 35 kg/m <sup>2</sup>          | 2.95 (1.24-7.02)          | <b>0.012</b>     | 4.43 (1.27-15.48)            | <b>0.020</b> |
| Smoking                             | 0.59 (0.25-1.36)          | 0.211            |                              |              |
| Drug use                            | 0.42 (0.16-1.15)          | 0.086            | 0.32 (0.08-1.23)             | 0.097        |
| Hypertension                        | 0.52 (0.22-1.19)          | 0.118            | 0.58 (0.19-1.75)             | 0.335        |
| Prediabetes or diabetes             | 0.93 (0.41-2.13)          | 0.862            |                              |              |
| CD4 > 200 cells/mm <sup>3</sup>     | 0.49 (0.18-1.34)          | 0.156            | 0.71 (0.18-2.84)             | 0.311        |
| HIV RNA < 20 copies/mL              | 0.43 (0.05-3.70)          | 0.428            |                              |              |
| Tenofovir-based ART                 | 1.37 (0.41-4.53)          | 0.606            |                              |              |
| NNRI-based ART                      | 1.26 (0.48-3.28)          | 0.641            |                              |              |
| PI-based ART                        | 0.81 (0.32-2.05)          | 0.651            |                              |              |
| INSTI-based ART                     | 1.01 (0.44-2.30)          | 0.985            |                              |              |
| ACE-I or ARB use                    | 1.18 (0.50-2.75)          | 0.709            |                              |              |
| Statin use                          | 0.48 (0.20-1.18)          | 0.106            | 0.71 (0.18-2.84)             | 0.623        |
| Insulin use n (%)                   | 0.88 (0.17-4.63)          | 0.885            |                              |              |
| Metformin use                       | 0.42 (0.11-1.53)          | 0.177            | 0.44 (0.07-4.99)             | 0.641        |
| Platelets < 150 x10 <sup>9</sup> /L | 4.61 (1.73-12.28)         | <b>0.001</b>     | 4.85 (1.27-18.62)            | <b>0.021</b> |
| AST > 35 IU/L                       | 4.07 (1.51-19.94)         | <b>0.004</b>     | 2.51 (0.63-10.1)             | 0.193        |
| ALT > 35 IU/L                       | 0.67 (0.29-1.54)          | 0.343            |                              |              |
| Total bilirubin > 1.2 mg/dL         | 1.85 (0.76-4.54)          | 0.174            | 1.06 (0.25-4.40)             | 0.940        |
| Direct bilirubin > 0.3 mg/dL        | 2.21 (0.95-5.13)          | 0.061            | 1.06 (0.29-3.84)             | 0.925        |
| Albumin < 3.5 g/dL                  | 8.24 (3.27-20.77)         | <b>&lt;0.001</b> | 9.01 (2.39-33.91)            | <b>0.001</b> |
| Total cholesterol > 200 mg/dL       | 0.68 (0.27-1.72)          | 0.418            |                              |              |
| HDL-C < 40 mg/dL                    | 0.91 (0.40-2.11)          | 0.833            |                              |              |
| LDL-C > 100 mg/dL                   | 0.78 (0.34-1.79)          | 0.551            |                              |              |
| Triglycerides > 150 mg/dL           | 2.00 (0.80-4.99)          | 0.135            | 1.74 (0.55-5.47)             | 0.343        |

ACE-I, angiotensin-converting enzyme inhibitor; APRI, aspartate aminotransferase (AST) to platelet ratio index; ARB, angiotensin receptor blocker; ART, antiretroviral therapy; BARD score, body mass index, AST/alanine transaminase (ALT) ratio and diabetes score; FIB-4, fibrosis index based on 4 factors; HIV, human immunodeficiency virus; INSTI, integrase strand transfer inhibitor; HDL-C, high density lipoprotein; LDL-C, low density lipoprotein; NAFLD, nonalcoholic fatty liver disease; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitors; PWH, people with HIV; RNA, ribonucleic acid.

## REFERENCES

1. Godoy-Matos AF, Silva Júnior WS, Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. *Diabetol Metab Syndr*. 2020;12:60.
2. Kalligeros M, Vassilopoulos A, Shehadeh F, Vassilopoulos S, Lazaridou I, Mylonakis E, Promrat K, Wands JR. Prevalence and Characteristics of Nonalcoholic Fatty Liver Disease and Fibrosis in People Living With HIV Mono-infection: A Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol*. 2023:S1542-3565(23)00028-9.
3. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. *Clin Gastroenterol Hepatol*. 2012;10(12):1342-1359.e2.
4. Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, Duseja A, Eguchi Y, Wong VW, Negro F, Yilmaz Y, Romero-Gomez M. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. *Clinical gastroenterology and hepatology*. 2019;17(4):748-55.
5. Maurice JB, Patel A, Scott AJ, Patel K, Thursz M, Lemoine M. Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection. *AIDS*. 2017;31(11):1621-1632.
6. Zhang L, Bansal MB. Role of Kupffer Cells in Driving Hepatic Inflammation and Fibrosis in HIV Infection. *Front Immunol*. 2020;11:1086
7. Mosoian A, Zhang L, Hong F, Cunyat F, Rahman A, Bhalla R, Panchal A, Saiman Y, Fiel MI, Florman S, Roayaie S, Schwartz M, Branch A, Stevenson M, Bansal MB. Frontline Science: HIV infection of Kupffer cells results in an amplified proinflammatory response to LPS. *J Leukoc Biol*. 2017;101(5):1083-1090.
8. Cao YZ, Dieterich D, Thomas PA, Huang YX, Mirabile M, Ho DD. Identification and quantitation of HIV-1 in the liver of patients with AIDS. *AIDS*. 1992;6(1):65-70.
9. Kardashian A, Peters MG, Tien PC, Price JC. The Pathogenesis of Liver Disease in People Living With Human Immunodeficiency Virus: The Emerging Role of the Microbiome. *Clin Liver Dis (Hoboken)*. 2020;15(1):46-51.
10. Seth A, Sherman KE. Fatty liver disease in persons with HIV infection. *Top Antivir Med*. 2019;27(2):75-82.
11. Margolis AM, Heverling H, Pham PA, Stolbach A. A review of the toxicity of HIV medications. *J Med Toxicol*. 2014;10(1):26-39.
12. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. *AIDS*. 2003;17 Suppl 1:S141-8.
13. Sax PE, Erlandson KM, Lake JE, Mccomsey GA, Orkin C, Esser S, Brown TT, Rockstroh JK, Wei X, Carter CC, Zhong L, Brainard DM, Melbourne K, Das M, Stellbrink HJ, Post FA, Waters L, Koethe JR. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. *Clin Infect Dis*. 2020;71(6):1379-1389.



14. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. *Hepatology*. 2018;67(1):328-357.
15. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol*. 2016;64(6):1388-402.
16. de Lédinghen V, Vergniol J, Capdepon M, Chermak F, Hiriart JB, Cassinotto C, Merrouche W, Foucher J, Brigitte le B. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. *J Hepatol*. 2014;60(5):1026-31.
17. Bischoff J, Gu W, Schwarze-Zander C, Boesecke C, Wasmuth JC, van Bremen K, Dold L, Rockstroh JK, Trebicka J. Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART). *EClinicalMedicine*. 2021;40:101116.
18. Vergara S, Macías J, Rivero A, Gutiérrez-Valencia A, González-Serrano M, Merino D, Ríos MJ, García-García JA, Camacho A, López-Cortés L, Ruiz J, de la Torre J, Viciano P, Pineda JA; Grupo para el Estudio de las Hepatitis Viricas de la SAEI. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. *Clin Infect Dis*. 2007;45(8):969-74.
19. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. *Hepatology*. 2007;45(4):846-54.
20. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. *Gut*. 2008;57(10):1441-7.
21. Busca C, Sánchez-Conde M, Rico M, Rosas M, Valencia E, Moreno A, Moreno V, Martín-Carbonero L, Moreno S, Pérez-Valero I, Bernardino JI, Arribas JR, González J, Oliveira A, Castillo P, Abadía M, Guerra L, Mendez C, Montes ML. Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens. *Open Forum Infect Dis*. 2022;9(7):ofac279.
22. Altamirano J, Qi Q, Choudhry S, Abdallah M, Singal AK, Humar A, Bataller R, Borhani AA, Duarte-Rojo A. Non-invasive diagnosis: non-alcoholic fatty liver disease and alcoholic liver disease. *Transl Gastroenterol Hepatol*. 2020;5:31.
23. Centers for Disease Control and Prevention (2023). About Adult BMI. Healthy Weight, Nutrition, and Physical Activity. [https://www.cdc.gov/healthyweight/assessing/bmi/adult\\_bmi/index.html](https://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html) Accessed March 6, 2023).
24. American Diabetes Association (2018). Diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2014;37 Suppl 1:S81-90.

25. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbigele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension*. 2018;71(6):e13-e115.
26. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation*. 2009;120(16):1640-5.
27. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology*. 2003;38(2):518-26.
28. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology*. 2006;43(6):1317-25.
29. Kim D, Cholankeril G, Loomba R, Ahmed A. Prevalence of Fatty Liver Disease and Fibrosis Detected by Transient Elastography in Adults in the United States, 2017-2018. *Clin Gastroenterol Hepatol*. 2021;19(7):1499-1501.e2.
30. Vodkin I, Valasek MA, Bettencourt R, Cachay E, Loomba R. Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study. *Aliment Pharmacol Ther*. 2015;41(4):368-78.
31. Sterling RK, Smith PG, Brunt EM. Hepatic steatosis in human immunodeficiency virus: a prospective study in patients without viral hepatitis, diabetes, or alcohol abuse. *J Clin Gastroenterol*. 2013;47(2):182-7.
32. Vuille-Lessard É, Lebouché B, Lennox L, Routy JP, Costiniuk CT, Pexos C, Giannakis A, Szabo J, Klein MB, Sebastiani G. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients. *AIDS*. 2016;30(17):2635-2643.
33. Ingiliz P, Valantin MA, Duvivier C, Medja F, Dominguez S, Charlotte F, Tubiana R, Poynard T, Katlama C, Lombès A, Benhamou Y. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. *Hepatology*. 2009;49(2):436-42.

34. Guaraldi G, Squillace N, Stentarelli C, Orlando G, D'Amico R, Ligabue G, Fiocchi F, Zona S, Loria P, Esposito R, Palella F. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. *Clin Infect Dis*. 2008 Jul 15;47(2):250-7.
35. Van Welzen BJ, Mudrikova T, El Idrissi A, Hoepelman AIM, Arends JE. A Review of Non-Alcoholic Fatty Liver Disease in HIV-Infected Patients: The Next Big Thing? *Infect Dis Ther*. 2019 Mar;8(1):33-50.
36. Denkmayr L, Feldman A, Stechemesser L, Eder SK, Zandanell S, Schranz M, Strasser M, Huber-Schönauer U, Buch S, Hampe J, Paulweber B, Lackner C, Haufe H, Sotlar K, Datz C, Aigner E. Lean Patients with Non-Alcoholic Fatty Liver Disease Have a Severe Histological Phenotype Similar to Obese Patients. *J Clin Med*. 2018;7(12):562.
37. Cervo A, Milic J, Mazzola G, Schepis F, Petta S, Krahn T, Lebouche B, Deschenes M, Cascio A, Guaraldi G, Sebastiani G. Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus. *Clin Infect Dis*. 2020;71(10):e694-e701.
38. Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, Kechagias S. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. *Hepatol Commun*. 2017 Nov 30;2(1):48-57.
39. Feldman A, Eder SK, Felder TK, Kedenko L, Paulweber B, Stadlmayr A, Huber-Schönauer U, Niederseer D, Stickel F, Auer S, Haschke-Becher E, Patsch W, Datz C, Aigner E. Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver. *Am J Gastroenterol*. 2017;112(1):102-110.
40. Yoshida K, Yokota K, Kutsuwada Y, Nakayama K, Watanabe K, Matsumoto A, Miyashita H, Khor SS, Tokunaga K, Kawai Y, Nagasaki M, Iwamoto S. Genome-Wide Association Study of Lean Nonalcoholic Fatty Liver Disease Suggests Human Leukocyte Antigen as a Novel Candidate Locus. *Hepatol Commun*. 2020;4(8):1124-1135.
41. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. *Gut*. 2010;59(9):1265-9.
42. Sebastiani G, Milic J, Gioe C, Al Hinai AS, Cervo A, Lebouche B, Deschenes M, Cascio A, Mazzola G, Guaraldi G. Diagnosis of liver fibrosis in ageing patients with HIV at risk for non-alcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway. *Lancet HIV*. 2022;9 Suppl 1:S4.
43. Lu SN, Wang JH, Liu SL, Hung CH, Chen CH, Tung HD, Chen TM, Huang WS, Lee CM, Chen CC, Changchien CS. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. *Cancer*. 2006;107(9):2212-22.
44. Shima T, Uto H, Ueki K, Kohgo Y, Yasui K, Nakamura N, Nakatou T, Takamura T, Kawata S, Notsumata K, Sakai K, Tateishi R, Okanoue T. Hepatocellular carcinoma as a leading cause of cancer-related deaths in Japanese type 2 diabetes mellitus patients. *J Gastroenterol*. 2019;54(1):64-77.

45. Kaneda H, Hashimoto E, Yatsuji S, Tokushige K, Shiratori K. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease. *J Gastroenterol Hepatol*. 2006;21(9):1459-65.
46. Okanoue T, Shima T, Mitsumoto Y, Umemura A, Yamaguchi K, Itoh Y, Yoneda M, Nakajima A, Mizukoshi E, Kaneko S, Harada K. Artificial intelligence/neural network system for the screening of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. *Hepatol Res*. 2021;51(5):554-569.
47. Zhao P, Yan J, Pan B, Liu J, Fu S, Cheng J, Wang L, Jing G, Li Q. Association Between the Risk of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease. *Diabetes Metab Syndr Obes*. 2022;15:1141-1151.
48. Mikolasevic I, Lukenda V, Racki S, Milic S, Sladoje-Martinovic B, Orlic L. Nonalcoholic fatty liver disease (NAFLD) - a new factor that interplays between inflammation, malnutrition, and atherosclerosis in elderly hemodialysis patients. *Clin Interv Aging*. 2014;9:1295-303.
49. Kawaguchi K, Sakai Y, Terashima T, Shimode T, Seki A, Orita N, Takeshita Y, Shimakami T, Takatori H, Arai K, Kitamura K, Yamashita T, Yamashita T, Takamura M, Mizukoshi E, Takamura T, Honda M, Wada T, Kaneko S. Decline in serum albumin concentration is a predictor of serious events in nonalcoholic fatty liver disease. *Medicine (Baltimore)*. 2021;100(31):e26835.
50. Eslami L, Merat S, Malekzadeh R, Nasser-Moghadam S, Aramin H. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. *Cochrane Database Syst Rev*. 2013;(12):CD008623.
51. Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. *J Clin Gastroenterol*. 2009;43(10):990-4.
52. Volpe S, Lisco G, Fanelli M, Racaniello D, Colaianni V, Triggiani D, Donghia R, Crudele L, Rinaldi R, Sabbà C, Triggiani V, De Pergola G, Piazzolla G. Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study. *Nutrients*. 2022;14(21):4673.
53. Zhang X, Wong GL, Yip TC, Tse YK, Liang LY, Hui VW, Lin H, Li GL, Lai JC, Chan HL, Wong VW. Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease. *Hepatology*. 2022;76(2):469-482.
54. Rakoski MO, Singal AG, Rogers MA, Conjeevaram H. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. *Aliment Pharmacol Ther*. 2010 Nov;32(10):1211-21.
55. Li Y, Liu L, Wang B, Wang J, Chen D. Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. *Biomed Rep*. 2013;1(1):57-64.

56. Patel Chavez C, Cusi K, Kadiyala S. The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. *J Clin Endocrinol Metab.* 2022;107(1):29-38.
57. Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoué T, Ratziu V, Sanyal AJ, Sejling AS, Harrison SA; NN9931-4296 Investigators. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. *N Engl J Med.* 2021;384(12):1113-1124.
58. Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kjær MS, Krarup N, Lawitz E, Ratziu V, Sanyal AJ, Schattenberg JM, Newsome PN; NN9931-4492 investigators. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. *Lancet Gastroenterol Hepatol.* 2023;8(6):511-522.
59. Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Sundby Palle M, Vogl T, Loomba R, Plum-Mörschel L. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. *Aliment Pharmacol Ther.* 2021;54(9):1150-1161.
60. Bakasis AD, Androutsakos T. Liver Fibrosis during Antiretroviral Treatment in HIV-Infected Individuals. *Truth or Tale? Cells.* 2021;10(5):1212.
61. Pérez-Matute P, Pérez-Martínez L, Blanco JR, Oteo JA. Role of mitochondria in HIV infection and associated metabolic disorders: focus on nonalcoholic fatty liver disease and lipodystrophy syndrome. *Oxid Med Cell Longev.* 2013;2013:493413.
62. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *J Clin Invest.* 2003;112(12):1821-30.